Welcome to SaxendaCare®

Register
Forgot my password

Saxenda® (liraglutide (rys) 6 mg/mL) is a prescription medicine indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of ≥30 kg/m2 (obese) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Before prescribing Saxenda® please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is available at http://www.medsafe.govt.nz.

Privacy Policy | Term of Use
Copyright© Novo Nordisk A/S 2020. Novo Nordisk Pharmaceuticals Ltd., G.S.T. 53 960 898. Office 1625, Level 16 ǀ PWC Tower, 15 Customs Street West ǀ Commercial Bay ǀ Auckland 1010, New Zealand.
Novo Nordisk Medical Information (NZ) 0800 733 737 www.novonordisk.co.nz. ® Registered trademark of Novo Nordisk A/S. NZ24SX00070. TAPS BG3325. Last updated October 2024.
×

/*Terms of Use */

×

/*Privacy Policy Australia and New Zealand*/

If you have forgotten your password you can reset it here.

SAXENDACARE® REGISTRATION

loading gif